

Table S1. Quality assessment of the included RCTs based on the three items Jadad scale

Studies	Tachibana	Cao	Lv
Description of randomization	Yes	Yes	Yes
Description of the right method of randomization	No	No	Yes
Description of the dropouts and withdrawals	Yes	Yes	Yes
Jadad score	2	2	3

Table S2. MINORS score of all eligible NRCTs

Studies	Saito 1993	Mukaida 1998	Bédard 2001	Rice 2003	Liu 2005	Chen 2011,2013	Wang 2014	Hsu 2014	Hwang 2016	Hsu 2017
A clearly stated aim	2	2	2	2	2	2	2	2	2	2
Inclusion of consecutive patients	2	0	2	2	2	2	2	1	2	2
Prospective collection of data	2	2	2	2	2	1	2	2	0	0
Endpoints appropriate to the aim of the study	2	1	2	1	2	1	2	2	2	2
Unbiased assessment of the study endpoint	0	0	0	0	0	0	0	0	0	0
Follow-up period appropriate to the aim of the study	2	1	2	1	2	2	2	2	2	2
Loss to follow up less than 5%	2	2	2	2	2	2	1	1	2	2
Prospective calculation of the study size	0	0	0	0	2	0	0	0	0	0
An adequate control group	2	2	2	2	2	2	2	2	2	2
Contemporary groups	0	2	2	2	2	2	2	2	2	2
Baseline equivalence of groups	2	2	2	2	2	1	1	1	2	2
Adequate statistical analyses	2	2	2	2	2	2	2	2	2	2
MINORS score	18	16	20	18	22	17	18	17	18	18

The items are scored 0 (not reported), 1 (reported but inadequate) or 2 (reported and adequate).

Table S3. Meta-analysis outcomes of toxicities comparison between postoperative CCRT versus postoperative CT/RT

Outcomes	Included studies	Sample size		Analysis model	Test for overall effect		I ² value for heterogeneity
		CCRT	CT/RT		OR (95% CI)	P	
G3-4 anemia	2	52	53	F	1.26 (0.34-4.73)	0.730	0%
G3-4 Thrombocytopenia	2	52	53	F	0.84 (0.25-2.82)	0.770	20%
Esophagitis	2	194	170	F	1.71 (1.09-2.66)	0.020	0%
Pneumonitis	2	194	170	F	0.89 (0.55-1.44)	0.630	0%
Anastomotic stenosis	2	194	170	F	0.54(0.18-1.59)	0.260	0%

Abbreviations: CCRT: concurrent chemoradiotherapy; CT/RT: chemotherapy or radiotherapy; F: fixed-effects model, OR: odds ratio; CI: confidence interval; G 3-4: grade 3-4